Skip to main content
. 2024 Feb 6;14(5):766–785. doi: 10.1158/2159-8290.CD-23-0857

Figure 2.

Figure 2. A single cycle of 5-FU/platinum remodels the TME in advanced gastric cancer. A, Changes in enrichment in bulk RNA-seq data of immune-related pathways from baseline (Base) to FU1. Statistical comparison performed using a Wilcoxon signed-rank test. B, UMAP embedding of single-cell transcriptomes obtained from all samples in this trial. Labeled are canonical cell types. C, Cell-type proportions, obtained from scRNAseq data, in adjacent normal, distance normal and tumor tissue, at baseline (BL) and after 1 cycle of chemotherapy (FU1). D, Redistribution of TME subtypes following one cycle of 5FU/platinum chemotherapy. TME subtypes were obtained using a classification performed on bulk RNA-seq data. E, Cell type proportions, obtained from scRNAseq data, in tumor samples of fast and slow progressing patients at BL and FU1.

A single cycle of 5-FU/platinum remodels the TME in advanced gastric cancer. A, Changes in enrichment in bulk RNA-seq data of immune-related pathways from baseline (Base) to FU1. Statistical comparison performed using a Wilcoxon signed-rank test. B, UMAP embedding of single-cell transcriptomes obtained from all samples in this trial. Labeled are canonical cell types. C, Cell-type proportions, obtained from scRNAseq data, in adjacent normal, distance normal and tumor tissue, at baseline (BL) and after 1 cycle of chemotherapy (FU1). D, Redistribution of TME subtypes following one cycle of 5FU/platinum chemotherapy. TME subtypes were obtained using a classification performed on bulk RNA-seq data. E, Cell type proportions, obtained from scRNAseq data, in tumor samples of fast and slow progressing patients at BL and FU1.